Liver Cancer Trial, Recruiting NCT06986486 Sponsor: Fondazione IRCCS Istituto Nazionale dei Tumori, Milano Condition: Liver Cancer
Back to Liver Cancer

Liver Cancer Trial, Recruiting

NCT06986486
Recruiting Not Applicable

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • People diagnosed with a specific type of bile duct cancer (called unresectable peripheral cholangiocarcinoma) that cannot be surgically removed, is located at least 1 centimeter above the upper edge of the pancreas, and has a tumor no larger than 3 centimeters
  • The diagnosis must have been confirmed by one of the following: a tissue or cell sample taken through a catheter procedure; a specific blood marker (CA-19.9) above a certain level and/or a growth seen on a scan with signs of a blocked bile duct; or a special chromosome test (called FISH) showing signs of cancer alongside a blocked bile duct appearance
  • People aged between 18 and 70 years old
  • People with no evidence that the cancer has spread inside or outside the liver
  • People with no evidence that the cancer has spread to any lymph nodes
  • People who have had stents (small tubes) placed to keep all areas of the bile ducts open across the liver
  • People who have no medical reasons preventing them from having a liver transplant
  • People with no other current cancers and no history of another cancer in the past 5 years
  • People who have given written agreement to take part in the trial

Who may not be able to join:

  • People whose bile duct cancer originates inside the liver (called intrahepatic cholangiocarcinoma)
  • People with an active infection that is not under control
  • People who currently have another cancer, or who have had a different cancer within the past 5 years

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 27 July 2026
This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.

Contact this trial

Phone: 0223902760

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Not Applicable
Sponsor
Fondazione IRCCS Istituto Nazionale dei Tumori, Milano
Registry
ClinicalTrials.gov
Start date
1 June 2025
Est. completion
1 January 2030

Where this trial is recruiting

🇮🇹 Italy

Primary endpoints

3-year overall survival

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 27 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov